APA (7th ed.) Citation

S, I., FS, S., N, D., G, P., J, V., K, M., . . . EO, P. (2019). Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG. Disease models & mechanisms, 12(11), . https://doi.org/10.1242/dmm.040584

Chicago Style (17th ed.) Citation

S, Iyer, et al. "Repurposing the Aldose Reductase Inhibitor and Diabetic Neuropathy Drug Epalrestat for the Congenital Disorder of Glycosylation PMM2-CDG." Disease Models & Mechanisms 12, no. 11 (2019). https://doi.org/10.1242/dmm.040584.

MLA (9th ed.) Citation

S, Iyer, et al. "Repurposing the Aldose Reductase Inhibitor and Diabetic Neuropathy Drug Epalrestat for the Congenital Disorder of Glycosylation PMM2-CDG." Disease Models & Mechanisms, vol. 12, no. 11, 2019, https://doi.org/10.1242/dmm.040584.